The Epidermolysis Bullosa Pipeline Insight report from DelveInsight offers a detailed overview of the pipeline therapies in various clinical and preclinical stages of growth, their introduction, and how the Epidermolysis Bullosa market is expected to change as a result.
Some of the Crucial Highlights from the Epidermolysis Bullosa Pipeline Report
- There are 30+ Epidermolysis Bullosa pipeline therapies in different stages of development, and their expected adoption in the Epidermolysis Bullosa market will significantly increase market revenue.
- Out of the emerging therapies, EB 101 is in Phase III of clinical development, whereas PTR-01 is in Phase II development phase for Epidermolysis Bullosa.
- Epidermolysis Bullosa pipeline therapies in the early stage of development include Ubidecarenone in Phase I of clinical trials.
- Some Epidermolysis Bullosa pipeline therapy including Ribosomal Modulators is still in the pre-clinical phase of development.
Request for sample @ Epidermolysis Bullosa Pipeline Insight and Outlook
The Epidermolysis Bullosa Pipeline Analysis report provides a 360-degree view of the therapeutics environment for Epidermolysis Bullosa evolving therapies, including development stage, product type, route of administration, molecule type, and MOA.
The pipeline report covers everything from business opportunities to challenges to future partnerships to strong rivals to growth strategies.
Epidermolysis Bullosa is a group of rare diseases that cause the skin to become brittle and blistered. Blisters may form as a result of minor trauma, such as fire, rubbing, scratching, or adhesive tape. Blisters may appear anywhere on the skin’s surface, inside the oral cavity, and in more extreme cases, the external surface of the eye, as well as the respiratory, gastrointestinal, and genitourinary tracts.
Read more about Epidermolysis Bullosa
Epidermolysis Bullosa: Symptoms
Symptoms of Epidermolysis Bullosa includes:
- Skin that blisters easily
- Blisters inside the mouth
- Blisters on the hands and soles of the feet
- Scarred skin
- Thickened skin and nails
Epidermolysis Bullosa has no known cure. Epidermolysis Bullosa is currently treated with symptomatic cures. The main goal is to protect the skin and prevent blisters from forming, as well as to encourage healing and avoid complications. Gene therapy and cell-based therapy are among the treatments in clinical trials to improve quality of life.
To learn more about disease, causes and treatment visit, Epidermolysis Bullosa Pipeline Landscape
B-VEC: Krystal Biotech
B-VEC is a replication-deficient HSV-1 vector with two functional COL7A1 genes that can be applied topically. B-VEC (Beremagene Geperpavec, formerly “KB103”) is a non-integrating viral vector based gene therapy that was engineered using Krystal’s Skin TARgeted Delivery platform, or STAR-D platform, to deliver functional human COL7A1 genes directly to patients’ dividing and non-dividing skin cells.
Key Pipeline Therapies and Major Pharmaceutical Companies
- EB 101: Abeona Therapeutics
- PTR-01: Phoenix Tissue Repair
- Ubidecarenone: Berg Pharma
- Ribosomal Modulators: Zikani Therapeutics
Gain more knowledge on emerging drugs @ Epidermolysis Bullosa Pipeline Therapies
- By Product Type
- Combination Therapy
- By Stage
- Phase I
- Phase II
- Phase III
- By Route of Administration
- By Molecule Type
- Small Molecule
- Stem Cell Therapy
- Gene Therapy
- Immune System
- Multiple Kinase
- By Mechanism of Action
- Protease Inhibitors
Reach out for more information @ Epidermolysis Bullosa Pipeline Assessment
Scope of the Report
Key Players: Abeona Therapeutics, Phoenix Tissue Repair, Berg Pharma, Zikani Therapeutics, among others.
Key Pipeline Therapies: EB 101, PTR-01, Ubidecarenone, Ribosomal Modulators, others.
Table of Contents
|3.||Epidermolysis Bullosa: Overview|
|4.||Epidermolysis Bullosa Pipeline Therapeutics|
|5.||Epidermolysis Bullosa Late Stage Products (Pre-registration)|
|6.||Epidermolysis Bullosa Late Stage Products (Phase III)|
|7.||Epidermolysis Bullosa Mid Stage Products (Phase II)|
|8.||Epidermolysis Bullosa Early Stage Products (Phase I)|
|9.||Epidermolysis Bullosa Pre-clinical and Discovery Stage Products|
|10.||Epidermolysis Bullosa Therapeutic Assessment|
|11.||Epidermolysis Bullosa Inactive Products|
|12.||Epidermolysis Bullosa: Unmet Needs|
|13.||Epidermolysis Bullosa: Market Drivers and Barriers|
Know more of what’s covered in the Epidermolysis Bullosa Pipeline Assessment Report
Key Questions Answered in the Epidermolysis Bullosa Report
- What are the current options for Epidermolysis Bullosa treatment?
- How many companies are developing therapies for the treatment of Epidermolysis Bullosa?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Epidermolysis Bullosa?
- How many Epidermolysis Bullosa emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Epidermolysis Bullosa?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Epidermolysis Bullosa?
Request for a Webex demo @ Epidermolysis Bullosa Pipeline and get a walk-through of our report
DelveInsight’s “Refractory Status Epilepticus – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Refractory status epilepticus pipeline landscape.
“Epilepsy Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Epilepsy market.
“Dystrophic Epidermolysis Bullosa Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Dystrophic Epidermolysis Bullosa market.
“Recessive Dystrophic Epidermolysis (RDEB) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Recessive Dystrophic Epidermolysis (RDEB) market.
“Drug Resistant Epilepsy Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Drug Resistant Epilepsy market.
“Epithelial Ovarian Cancer Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Epithelial Ovarian Cancer market.
Get comprehensive analysis of Pre-Eclampsia pipeline therapies and key companies including Pharming Group, MirZyme, Amag Pharmaceuticals, Kyowa Kirin Co., Ltd, among others.
Get comprehensive analysis of Relapsed or Refractory Myelodysplastic Syndrome pipeline therapies and key companies including such as Novartis, BioTheryX, Cantex Pharmaceuticals, Agios Pharmaceuticals, among others.
Get comprehensive analysis of Lymphatic Malformations pipeline therapies and key companies including Vanthera, Cerecor, Inc., Protara therapeutics, among others.
Get comprehensive analysis of Necrobiosis Lipoidica pipeline therapies and key companies including Novartis, Processa Pharmaceuticals, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at:
Sandeep Joshi email@example.com +1(919)321-6187